KGF: A Literature Course on Keratinocyte Growth Factor Research

How this course is organised

This page is for educational purposes only and is not medical advice; consult a licensed physician before making any decision related to health, medication or research participation. PeptideU sells nothing and links to no seller; it summarises what published papers reported so that readers can find and read those papers themselves.

The course runs in six modules. Module 1 covers definition, class, origin and forms. Module 2 covers mechanism as the literature described it. Module 3 lists reported outcomes study by study, with the model and endpoint attached to each result. Module 4 covers adverse or unintended findings as published. Module 5 covers pharmacokinetics, where data exist. Module 6 states regulatory status factually. A closing section lists what the cited studies did not test.

Two conventions apply throughout. First, every sentence that states an effect, endpoint or quantity carries a PubMed link to the paper it came from. Second, where the cited literature contains no data on a question, the module says so rather than filling the gap by inference. No dosing figures appear anywhere on this page, because the verified papers assembled for this course do not supply human dosing data.

Module 1 — What KGF is and how it has been studied

Definition and class

KGF is the abbreviation for keratinocyte growth factor, the protein catalogued in gene and protein databases as fibroblast growth factor 7 (FGF7). It belongs to the fibroblast growth factor (FGF) family: a group of secreted, heparin-binding signalling proteins that act through cell-surface FGF receptors. KGF is therefore a growth factor protein rather than one of the short synthetic peptide chains that are often discussed in the same breath. Its molecular size, glycosylation and receptor-binding behaviour place it with the FGF proteins, not with oligopeptides.

Origin and naming

The name reflects the biology that led to its discovery: it was characterised as a factor produced by mesenchymal cells, such as fibroblasts, that acts on epithelial cells including keratinocytes. That mesenchymal-to-epithelial direction of signalling is the organising idea behind most of the research literature.

Several related names appear in papers and can confuse a first reading:

• KGF / FGF7 — the original keratinocyte growth factor.
• KGF-2 / FGF10 — a related family member studied separately; a 2025 ocular study used KGF-2 and reported it alleviated dry eye disease in its model through the HMGB1/TLR4 pathway (PMID 40227178).
• KGFR — the receptor form addressed by KGF, referred to as KGFR in a 2020 asthma paper that described KGF/KGFR proliferative and anti-apoptosis functions in bronchial epithelial repair (PMID 32818548).
• Palifermin — a recombinant human KGF manufactured as a prescription biologic; see Module 6.

How the literature has studied it

The cited body of work is preclinical and mechanistic. Researchers have used cultured epithelial cells, tissue explants and animal injury models rather than human efficacy trials. Examples of the study designs include cultured middle ear mucosal cells, in which the study reported KGF induced stem/progenitor cell growth (PMID 31614241); oral epithelial models, in which researchers reported KGF enhanced epithelial adhesion and rete peg elongation via integrins (PMID 28732179); a cyclophosphamide bladder injury model, in which the study reported AKT signalling downstream of KGF was necessary and sufficient for blocking injury (PMID 35063403); and a thymocyte study in which researchers reported that disruption of Notch signalling by KGF induced a developmental pause (PMID 41357235).

Limits of the evidence in Module 1

Definitions are stable; the study base is not broad. The papers gathered here span different tissues, species, cell lines and years, and they were not designed as a coordinated programme. A reader cannot infer from these reports how KGF behaves in an intact human being, because none of the cited studies was a human clinical trial. Nomenclature is a practical limit too: results obtained with KGF-2/FGF10 (PMID 40227178) do not automatically describe KGF/FGF7, and the two should be read as separate proteins.

Module 2 — Mechanism as described in the literature

Across the cited papers, KGF signalling was described as receptor-mediated activation of intracellular kinase cascades in epithelial cells, with downstream changes in adhesion molecules, survival proteins and proliferation. The pathway elements named in each paper are listed below.

Reading the mechanism claims carefully

Two mechanistic themes recur. The first is survival: apoptosis was the endpoint in the intestinal hypoxia work, where researchers reported that KGF inhibited hypoxia-induced epithelial cell apoptosis (PMID 30021369), and anti-apoptosis function was named in the asthma paper (PMID 32818548). The second is adhesion and architecture: integrin expression was the readout in the C/EBPβ study (PMID 17596295) and epithelial adhesion with rete peg elongation was the readout in the oral study (PMID 28732179).

Limits of the evidence in Module 2

Mechanism is not outcome. A pathway identified in cultured cells or a single animal model shows that the pathway can be engaged, not that engaging it produces a benefit in people. Pathway papers also use tools — inhibitors, knockdowns, constitutively active constructs — that create conditions far from ordinary physiology; the AKT necessity-and-sufficiency framing in the bladder injury work is a statement about that experimental system (PMID 35063403). Finally, AKT, ERK, Notch and TLR4 are broadly shared pathways, so any intervention touching them can be expected to have effects beyond the tissue being studied.

Module 3 — Reported outcomes by study

This module restates each cited paper as model, endpoint and reported result. No benefit is promised or implied for any person, and no dosing figures are given, because the verified source list does not supply them.

Limits of the evidence in Module 3

Each row is one experiment in one system. The endpoints are cellular and histological — proliferation, apoptosis, adhesion protein expression, tissue architecture — rather than patient-centred outcomes such as symptoms, function or survival. Results in one epithelium do not transfer to another: middle ear findings (PMID 31614241) say nothing about bladder urothelium (PMID 35063403). Because none of these reports is a randomised human trial, effect sizes, durability and inter-individual variation remain unknown from this source set.

Module 4 — Kgf Side Effects: What Studies Report

The cited papers were designed as mechanism and repair studies, not as toxicology or safety trials, so none of them presents a human adverse-event table. What they do contain are findings that illustrate where unintended biology could arise.

Unintended or off-target findings in the cited work

• Developmental arrest in immune cells. Researchers reported that disruption of Notch signalling by KGF induced a developmental pause in thymocytes, an effect on immune cell maturation rather than on epithelial repair (PMID 41357235).
• Proliferation and apoptosis resistance as a mechanism, not a benefit. The asthma study described proliferative and anti-apoptosis functions of the KGF/KGFR axis (PMID 32818548), and the intestinal study reported inhibition of hypoxia-induced apoptosis (PMID 30021369); signalling that increases epithelial proliferation and reduces cell death is the reason growth-factor safety questions are studied at all.
• Broad pathway engagement. The pathways named across the set — AKT (PMID 35063403), integrin regulation via C/EBPβ (PMID 17596295) and TLR4-linked inflammatory signalling with KGF-2 (PMID 40227178) — are used by many tissues, so tissue selectivity cannot be assumed from these reports.

Limits of the evidence in Module 4

Absence of reported harm in a mechanistic paper is not evidence of safety; these studies did not look for harm systematically, did not follow subjects long-term, and did not report dose-limiting toxicity. Safety information for the licensed recombinant product exists in its FDA-approved prescribing information, which is the appropriate source for labelled warnings and adverse reactions and is not reproduced here. Anyone evaluating risk should read that labelling and speak with a licensed physician.

Module 5 — Pharmacokinetics where data exist

Within this verified source set, pharmacokinetic data do not exist. The cited reports are mechanistic studies in cells and animal injury models — for example the intestinal hypoxia apoptosis work (PMID 30021369), the middle ear mucosa culture work (PMID 31614241) and the bladder injury work (PMID 35063403) — and none of them reported plasma concentration curves, half-life, clearance or bioavailability in humans.

Some general expectations follow from protein class rather than from these papers. As a secreted glycoprotein, KGF is not an orally absorbed molecule; proteins of this type are given parenterally in clinical settings, and their disposition is governed by proteolysis and receptor-mediated clearance rather than hepatic small-molecule metabolism. That is background pharmacology, not a measured parameter, and it should not be read as a substitute for actual pharmacokinetic data.

Limits of the evidence in Module 5

Because no cited paper measured exposure, this course cannot state any dose, concentration, dosing interval or duration. Statements about how long KGF persists, how much reaches a given tissue, or how repeat administration accumulates cannot be supported by the sources above. Human pharmacokinetic parameters for the licensed recombinant product are published in its prescribing information.

Module 6 — Regulatory status

Approved product

A recombinant human keratinocyte growth factor, palifermin (marketed as Kepivance), is a licensed biologic product in the United States, approved under a Biologics License Application for decreasing the incidence and duration of severe oral mucositis in patients with haematologic malignancies receiving myelotoxic therapy requiring haematopoietic stem cell support. That means KGF is not a purely experimental molecule: one form of it is a prescription medicine with an approved indication, labelled warnings and an established manufacturing process. Its labelled use is narrow and hospital-based.

Research-use-only material

Recombinant KGF and KGF-2 are also supplied as research reagents. Research-use-only (RUO) material is intended for laboratory investigation only; it is not manufactured, tested or labelled as a drug for human use, and RUO labelling is not an authorisation for administration to people. The preclinical papers in this course used research-grade protein in laboratory systems.

Compounding

Compounding in the United States is governed by sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, which set out the conditions under which pharmacies and outsourcing facilities may prepare drug products and which bulk drug substances may be used. Biologic products licensed under a BLA are treated differently from small-molecule drugs under these provisions, and eligibility of any given substance for compounding depends on FDA lists and criteria that change over time. Nothing here is legal advice; regulatory and legal questions should be directed to a qualified professional, and clinical questions to a licensed physician.

Limits of the evidence in Module 6

Regulatory approval attaches to a specific product, formulation and indication — not to a molecule in general. The existence of an approved KGF product does not validate research-grade material, other routes, other tissues, or the preclinical endpoints described in Modules 2 and 3. Status also varies by country and changes over time, so the current authority is always the relevant regulator's own record.

What the studies did not test

Reading the eight papers together, the gaps are as important as the findings:

1. Healthy human use. Every cited experiment used cells, tissues or animal injury models; none tested KGF in healthy people for general wellness, recovery or appearance.
2. Dose-response in humans. No cited paper supplies a human dose, interval or duration, so none is stated on this page.
3. Long-term follow-up. Endpoints were short-term and cellular; the thymocyte developmental pause (PMID 41357235) and the proliferative/anti-apoptotic functions described in asthma (PMID 32818548) were not followed to long-term outcomes in these reports.
4. Cross-tissue generalisation. Ocular results obtained with KGF-2 (PMID 40227178) were not shown to predict oral (PMID 28732179) or bladder (PMID 35063403) outcomes.
5. Combinations. None of the cited studies evaluated KGF alongside other peptides, growth factors or supplements.
6. Comparative effectiveness. No cited study compared KGF with an established therapy for the same condition.

This page is educational. It reports what specific papers stated, with links so the primary sources can be read in full, and it makes no recommendation about use by any person.

References

• Disruption of Notch signaling by KGF induces a developmental pause in thymocytes (Frontiers in Immunology, 2025)
• KGF-2 Alleviates Dry Eye Disease by Regulating the HMGB1/TLR4 Pathway (Investigative Ophthalmology & Visual Science, 2025)
• Keratinocyte growth factor (KGF) induces stem/progenitor cell growth in middle ear mucosa (International Journal of Pediatric Otorhinolaryngology, 2020)
• KGF Enhances Oral Epithelial Adhesion and Rete Peg Elongation via Integrins (Journal of Dental Research, 2017)
• AKT Signaling Downstream of KGF Is Necessary and Sufficient for Blocking Cyclophosphamide Bladder Injury (The American Journal of Pathology, 2022)
• KGF inhibits hypoxia-induced intestinal epithelial cell apoptosis by upregulating AKT/ERK pathway-dependent E-cadherin expression (Biomedicine & Pharmacotherapy, 2018)
• KGF promotes integrin alpha5 expression through CCAAT/enhancer-binding protein-beta (American Journal of Physiology. Cell Physiology, 2007)
• The proliferative and anti-apoptosis functions of KGF/KGFR contributes to bronchial epithelial repair in asthma (Pulmonary Pharmacology & Therapeutics, 2020)